SCHEMBL5109097

SCHEMBL5109097

CCOC(=O)c1cc(NC(=O)COc2ccc(C(F)(F)F)cc2Cl)ccc1OCCN(CC)CC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 1/20 0.49
MCHR1 Q99705 3/20 0.45
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
POLB P06746 1/20 0.44
KDR P35968 1/20 0.44
PDE5A O76074 2/20 0.44
CETP P11597 2/20 0.43
PDE6D O43924 1/20 0.42
PDE6A P16499 1/20 0.42
PDE6G P18545 1/20 0.42
PDE6B P35913 1/20 0.42
PDE6C P51160 1/20 0.42
PDE6H Q13956 1/20 0.42
LMNA P02545 4/20 0.42
MAPT P10636 3/20 0.42
CHRM2 P08172 1/20 0.41
ADRA2A P08913 1/20 0.41
CHRM1 P11229 1/20 0.41
ADRA2B P18089 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4008980 0.91 MCHR1 (0.49) MRGPRX4MCHR1KMT2AMEN1KDR
SCHEMBL4010353 0.90 KDR (0.52) MCHR1KMT2AMEN1KDRLMNA
SCHEMBL4007957 0.89 KDR (0.47) MRGPRX4MCHR1KMT2AMEN1POLB
SCHEMBL13683763 0.88 MCHR1 (0.50) MRGPRX4MCHR1KDRCETPMAPT
SCHEMBL4010419 0.86 KDM4E (0.49) KMT2AMEN1KDRLMNAMAPT
SCHEMBL4004778 0.86 KDR (0.47) MCHR1KMT2AMEN1KDRLMNA
SCHEMBL4008881 0.86 KDR (0.47) MCHR1KMT2AMEN1KDRLMNA
SCHEMBL4008962 0.86 MCHR1 (0.54) MCHR1KMT2AMEN1KDRLMNA
SCHEMBL4008917 0.86 KDR (0.48) MCHR1KMT2AMEN1KDRLMNA
SCHEMBL5109832 0.85 MRGPRX4 (0.49) MRGPRX4KMT2AMEN1POLBPDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351719-B2 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2008-04-01 US disclosed
US-7351719-B2 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2008-04-01 US disclosed
US-7351719-B2 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2008-04-01 US disclosed
US-20040152742-A1 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152742-A1 Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds MCHR2, MCHR1, NPY1R MRGPRX4 45/4885MCHR1 2/4885KMT2A 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.